Emergent BioSolutions (EBS) Debt to Equity (2016 - 2025)
Emergent BioSolutions' Debt to Equity history spans 16 years, with the latest figure at $1.09 for Q4 2025.
- For Q4 2025, Debt to Equity fell 20.37% year-over-year to $1.09; the TTM value through Dec 2025 reached $1.09, down 20.37%, while the annual FY2025 figure was $1.09, 20.37% down from the prior year.
- Debt to Equity reached $1.09 in Q4 2025 per EBS's latest filing, down from $1.14 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $1.37 in Q4 2024 to a low of $0.32 in Q4 2022.
- Average Debt to Equity over 5 years is $0.78, with a median of $0.66 recorded in 2023.
- Peak YoY movement for Debt to Equity: crashed 35.65% in 2022, then skyrocketed 147.36% in 2024.
- A 5-year view of Debt to Equity shows it stood at $0.5 in 2021, then plummeted by 35.65% to $0.32 in 2022, then skyrocketed by 112.77% to $0.69 in 2023, then surged by 99.91% to $1.37 in 2024, then dropped by 20.37% to $1.09 in 2025.
- Per Business Quant, the three most recent readings for EBS's Debt to Equity are $1.09 (Q4 2025), $1.14 (Q3 2025), and $1.25 (Q2 2025).